Thursday, October 27, 2016

Methotrexate Oral, Injection



meth-oh-TREX-ate


Injection route(Powder for Solution;Solution)

Only for life-threatening neoplastic disease or severe rheumatoid arthritis and psoriasis unresponsive to other therapies. Death, fetal death and/or congenital anomalies, lung disease, tumor lysis syndrome, fatal skin reactions, and Pneumocystis carinii pneumonia have been reported. Monitor for bone marrow, liver, lung, and kidney toxicities. Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs). Hepatotoxicity, fibrosis, and cirrhosis occur with prolonged use. Diarrhea and ulcerative stomatitis require interruption of therapy. Methotrexate elimination is reduced in patients with impaired renal functions, ascites, or pleural effusions. Increased risk of soft tissue necrosis and osteosarcoma with concomitant radiotherapy. Malignant lymphoma may occur. Use extreme caution with high dose regimen for osteosarcoma. Do not use formulations/diluents with preservatives for intrathecal or high dose therapy .


Oral route(Tablet)

Only for life-threatening neoplastic disease or severe rheumatoid arthritis and psoriasis unresponsive to other therapies. Death, fetal death and/or congenital anomalies, lung disease, tumor lysis syndrome, fatal skin reactions, and Pneumocystis carinii pneumonia have been reported. Monitor for bone marrow, liver, lung, and kidney toxicities. Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs). Hepatotoxicity, fibrosis, and cirrhosis occur with prolonged use. Diarrhea and ulcerative stomatitis require interruption of therapy. Methotrexate elimination is reduced in patients with impaired renal functions, ascites, or pleural effusions. Increased risk of soft tissue necrosis and osteosarcoma with concomitant radiotherapy. Malignant lymphoma may occur .



Commonly used brand name(s)

In the U.S.


  • Rheumatrex Dose Pack

  • Trexall

Available Dosage Forms:


  • Tablet

  • Solution

  • Powder for Solution

  • Injectable

Therapeutic Class: Antineoplastic Agent


Pharmacologic Class: Antimetabolite


Uses For methotrexate


Methotrexate belongs to the group of medicines known as antimetabolites. It is used to treat cancer of the breast, head and neck, lung, blood, bone, and lymph, and tumors in the uterus. It may also be used to treat other kinds of cancer, as determined by your doctor.


Methotrexate blocks an enzyme needed by the cell to live. This interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by methotrexate, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Some effects may not occur for months or years after the medicine is used.


Before you begin treatment with methotrexate, you and your doctor should talk about the good methotrexate will do as well as the risks of using it.


Methotrexate is available only with your doctor's prescription.


Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, methotrexate is used in certain patients with the following medical conditions:


  • Acute nonlymphocytic leukemia (a type of cancer of the blood and lymph system)

  • Cancer in the membranes that cover and protect the brain and spinal cord (the meninges)

  • Cancer of the bladder

  • Cancer of the brain (lymphoma)

  • Cancer of the cervix

  • Cancer of colon and rectum

  • Cancer of the esophagus

  • Cancer of the ovaries

  • Cancer of the pancreas

  • Cancer of the penis

  • Cancers of the soft tissues of the body, including the muscles, connective tissues (tendons), vessels that carry blood or lymph, or fat

  • Cancer of the stomach

  • Hodgkin's lymphoma (a cancer of the lymph system, a part of the body's immune system)

Before Using methotrexate


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For methotrexate, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to methotrexate or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Newborns and other infants may be more sensitive to the effects of methotrexate. However, in other children it is not expected to cause different side effects or problems than it does in adults.


Geriatric


Side effects may be more likely to occur in the elderly, who are usually more sensitive to the effects of methotrexate.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersXStudies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. This drug should not be used in women who are or may become pregnant because the risk clearly outweighs any possible benefit.

Breast Feeding


Studies in women breastfeeding have demonstrated harmful infant effects. An alternative to this medication should be prescribed or you should stop breastfeeding while using methotrexate.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking methotrexate, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using methotrexate with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Rotavirus Vaccine, Live

Using methotrexate with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Adenovirus Vaccine Type 4, Live

  • Adenovirus Vaccine Type 7, Live

  • Alclofenac

  • Amoxicillin

  • Apazone

  • Asparaginase

  • Aspirin

  • Bacillus of Calmette and Guerin Vaccine, Live

  • Benoxaprofen

  • Bentiromide

  • Bismuth Subsalicylate

  • Carprofen

  • Dantrolene

  • Dexlansoprazole

  • Diclofenac

  • Diflunisal

  • Dipyrone

  • Doxycycline

  • Droxicam

  • Esomeprazole

  • Etodolac

  • Fenbufen

  • Fenoprofen

  • Flurbiprofen

  • Ibuprofen

  • Indomethacin

  • Indoprofen

  • Influenza Virus Vaccine, Live

  • Isoxicam

  • Ketoprofen

  • Ketorolac

  • Leflunomide

  • Measles Virus Vaccine, Live

  • Meclofenamate

  • Mefenamic Acid

  • Mezlocillin

  • Mumps Virus Vaccine, Live

  • Nabumetone

  • Naproxen

  • Nimesulide

  • Omeprazole

  • Oxaprozin

  • Pantoprazole

  • Penicillin G

  • Penicillin V

  • Phenylbutazone

  • Phenytoin

  • Piperacillin

  • Pirazolac

  • Piroxicam

  • Pirprofen

  • Pristinamycin

  • Probenecid

  • Proquazone

  • Pyrimethamine

  • Rabeprazole

  • Rotavirus Vaccine, Live

  • Rubella Virus Vaccine, Live

  • Salsalate

  • Smallpox Vaccine

  • Sulfamethizole

  • Sulfamethoxazole

  • Sulfapyridine

  • Sulfisoxazole

  • Sulindac

  • Suprofen

  • Tamoxifen

  • Tenidap

  • Tenoxicam

  • Tiaprofenic Acid

  • Tolmetin

  • Triamterene

  • Trimethoprim

  • Typhoid Vaccine

  • Varicella Virus Vaccine

  • Warfarin

  • Yellow Fever Vaccine

  • Zomepirac

Using methotrexate with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Amiodarone

  • Cyclosporine

  • Eltrombopag

  • Mercaptopurine

  • Procarbazine

  • Rofecoxib

  • Theophylline

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Other Medical Problems


The presence of other medical problems may affect the use of methotrexate. Make sure you tell your doctor if you have any other medical problems, especially:


  • Alcohol abuse (or history of)—Increased risk of unwanted effects on the liver

  • Chickenpox (including recent exposure) or

  • Herpes zoster (shingles)—Risk of severe disease affecting other parts of the body

  • Colitis

  • Disease of the immune system

  • Gout (history of) or

  • Kidney stones (or history of)—Methotrexate may increase levels of a chemical called uric acid in the body, which can cause gout or kidney stones

  • Infection—Methotrexate can reduce immunity to infection

  • Intestine blockage or

  • Kidney disease or

  • Liver disease—Effects may be increased because of slower removal of methotrexate from the body

  • Mouth sores or inflammation or

  • Stomach ulcer—May be worsened

Proper Use of methotrexate


Take methotrexate only as directed by your doctor. Do not take more or less of it, and do not take it more often than your doctor ordered. The exact amount of medicine you need has been carefully worked out. Taking too much may increase the chance of side effects, while taking too little may not improve your condition.


Methotrexate is often given together with certain other medicines. If you are using a combination of medicines, make sure that you take each one at the proper time and do not mix them. Ask your health care professional to help you plan a way to remember to take your medicines at the right times.


While you are using methotrexate, your doctor may want you to drink extra fluids so that you will pass more urine. This will help the drug to pass from the body, and will prevent kidney problems and keep your kidneys working well.


Methotrexate commonly causes nausea and vomiting. Even if you begin to feel ill, do not stop using methotrexate without first checking with your doctor. Ask your health care professional for ways to lessen these effects.


If you vomit shortly after taking a dose of methotrexate, check with your doctor. You will be told whether to take the dose again or to wait until the next scheduled dose.


Dosing


The dose of methotrexate will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of methotrexate. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


Missed Dose


If you miss a dose of methotrexate, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Call your doctor or pharmacist for instructions.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using methotrexate


It is very important that your doctor check your progress at regular visits to make sure that methotrexate is working properly and to check for unwanted effects.


Do not drink alcohol while using methotrexate. Alcohol can increase the chance of liver problems.


Some patients who take methotrexate may become more sensitive to sunlight than they are normally. When you first begin taking methotrexate, avoid too much sun and do not use a sunlamp until you see how you react to the sun, especially if you tend to burn easily. In case of a severe burn, check with your doctor.


Do not take medicine for inflammation or pain (aspirin or other salicylates, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, naproxen, phenylbutazone, piroxicam, sulindac, suprofen, tolmetin) without first checking with your doctor. These medicines may increase the effects of methotrexate, which could be harmful.


While you are being treated with methotrexate, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. Methotrexate may lower your body's resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid other persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, you should consider wearing a protective face mask that covers the nose and mouth.


Methotrexate can lower the number of white blood cells in your blood temporarily, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:


  • If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

  • Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in urine or stools; or pinpoint red spots on your skin.

  • Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

  • Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.

  • Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

  • Avoid contact sports or other situations where bruising or injury could occur.

methotrexate Side Effects


Along with their needed effects, medicines like methotrexate can sometimes cause unwanted effects such as blood problems, kidney problems, stomach or liver problems, loss of hair, and other side effects. These and others are described below. Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.


Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Black, tarry stools

  • blood in urine or stools

  • bloody vomit

  • diarrhea

  • joint pain

  • reddening of skin

  • stomach pain

  • swelling of feet or lower legs

Less common
  • Blurred vision

  • confusion

  • convulsions (seizures)

  • cough

  • pinpoint red spots on skin

  • shortness of breath

  • unusual bleeding or bruising

Check with your doctor as soon as possible if any of the following side effects occur:


More common
  • Sores in mouth and on lips

Less common
  • Back pain

  • cough or hoarseness accompanied by fever or chills

  • dark urine

  • dizziness

  • drowsiness

  • fever or chills

  • headache

  • lower back or side pain accompanied by fever or chills

  • painful or difficult urination accompanied by fever or chills

  • unusual tiredness or weakness

  • yellow eyes or skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Loss of appetite

  • nausea or vomiting

Less common
  • Acne

  • boils

  • pale skin

  • skin rash or itching

methotrexate may cause a temporary loss of hair in some people. After treatment with methotrexate has ended, normal hair growth should return.


After you stop using methotrexate, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:


  • Back pain

  • blurred vision

  • confusion

  • convulsions (seizures)

  • dizziness

  • drowsiness

  • fever

  • headache

  • unusual tiredness or weakness

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: methotrexate Oral, Injection side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More methotrexate Oral, Injection resources


  • Methotrexate Oral, Injection Side Effects (in more detail)
  • Methotrexate Oral, Injection Use in Pregnancy & Breastfeeding
  • Drug Images
  • Methotrexate Oral, Injection Drug Interactions
  • Methotrexate Oral, Injection Support Group
  • 42 Reviews for Methotrexate Oral, Injection - Add your own review/rating


Compare methotrexate Oral, Injection with other medications


  • Acute Lymphoblastic Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Nonlymphocytic Leukemia
  • Bladder Cancer
  • Brain Tumor
  • Breast Cancer
  • Bullous Pemphigoid
  • Cervical Cancer
  • Choriocarcinoma
  • Cogan's Syndrome
  • Colorectal Cancer
  • Dermatomyositis
  • Ectopic Pregnancy
  • Eczema
  • Esophageal Carcinoma
  • Gastric Cancer
  • Graft-versus-host disease
  • Head and Neck Cancer
  • Hodgkin's Lymphoma
  • Lymphoma
  • Meningeal Leukemia
  • Mycosis Fungoides
  • Neoplastic Diseases
  • Non-Hodgkin's Lymphoma
  • Non-Small Cell Lung Cancer
  • Osteosarcoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Pemphigoid
  • Pemphigus
  • Pityriasis rubra pilaris
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Small Cell Lung Cancer
  • Soft Tissue Sarcoma
  • Solid Tumors
  • Systemic Sclerosis
  • Trophoblastic Disease
  • Uveitis


Warfarin Tablets



Pronunciation: WAR-far-in
Generic Name: Warfarin
Brand Name: Coumadin

Warfarin can cause severe and sometimes fatal bleeding. Bleeding is more likely to occur at the start of treatment or with high doses. Patients who have a history of stomach or bowel bleeding, high blood pressure, stroke or "mini-stroke" (transient ischemic attack [TIA]), serious heart disease, anemia, cancer, certain genetic factors, or kidney problems may be at greater risk for bleeding. Patients who have inconsistent international normalized ratios (INRs; a blood test), who have taken Warfarin for a long time, who take certain other medicines, who have had a recent injury or surgery, or who are 65 years old or older are also at greater risk.


Certain blood clotting tests (eg, prothrombin time [PT], INR) will be performed regularly while you take Warfarin. Certain medicines, dietary changes, and other factors may affect INR levels while taking Warfarin. Discuss any questions or concerns with your doctor.


Contact your doctor right away if you notice any unusual bleeding or bruising. Symptoms of bleeding problems include unusual bruising; bleeding gums; bloody or coffee ground-like vomit; coughing up blood; dizziness; increased bleeding from cuts; increased menstrual or vaginal bleeding; nosebleeds, pain, swelling, or discomfort; pink or brown urine; red or black stools; unusual headaches or weakness.





Warfarin is used for:

Treating or preventing blood clots that may occur in the veins and lungs. It is used to treat or prevent blood clots that may occur because of a certain type of abnormal heartbeat (atrial fibrillation) or heart valve replacement. It is also used to reduce the risk of death, recurring heart attack, or blood clotting events (eg, stroke) after a heart attack. It may also be used for other conditions as determined by your doctor.


Warfarin is an anticoagulant. It works by blocking the formation of certain blood clotting factors.


Do NOT use Warfarin if:


  • you are allergic to any ingredient in Warfarin

  • you have bleeding tendencies, bleeding problems (eg, hemophilia), severe or uncontrolled high blood pressure, certain blood problems (eg, low white blood cell or platelet levels), or leukemia

  • you have active serious bleeding, bleeding in the brain, certain blood vessel problems (eg, aneurysm, dissecting aorta), or inflammation or infection of the heart

  • you have active ulcer or bleeding of the stomach or bowel, urinary tract, genitals, or respiratory tract

  • you have recently had or will be having eye, brain, or spinal cord surgery; spinal puncture; spinal anesthesia; or any type of major surgery

  • you are pregnant, unless you have a mechanical heart valve

  • you are unable to have routine blood clotting tests

  • you are unable to follow your doctor's instructions properly and do not have someone to help you take your medicine

  • you are taking mifepristone, streptokinase, or urokinase

Contact your doctor or health care provider right away if any of these apply to you.



Before using Warfarin:


Some medical conditions may interact with Warfarin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are able to become pregnant

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines or other substances

  • if you have recently been injured, fallen, given birth, or had surgery

  • if you have a history of stomach or bowel problems (eg, bleeding, ulcer, inflammation), heart problems (eg, heart failure, infection), blood clots, anemia or other blood problems (eg, protein C deficiency, high red blood cell levels), blood vessel problems, or high blood pressure

  • if you have a history of liver, kidney, or thyroid problems; yellowing of the skin or eyes; mental or mood problems; high cholesterol; arthritis; diabetes; or cancer

  • if you smoke or drink alcohol, or if you have poor nutrition, celiac disease, nutrient or fat absorption problems, or low levels of vitamin K or vitamin C in the blood

  • if you have a fever, very poor health, diarrhea, fluid buildup, excessive fat in the stools (steatorrhea), a recent or current infection, or tuberculosis, or if you will be exposed to high temperatures for a prolonged period of time

  • if you have a heart valve replacement, an intrauterine device (IUD), or a catheter

  • if you fall often, or if you plan to have any surgery or dental procedure

Some MEDICINES MAY INTERACT with Warfarin. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Antiplatelet medicines (eg, clopidogrel), heparin or other anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), salicylates (eg, aspirin), streptokinase, or urokinase because the risk of bleeding may be increased

  • Mifepristone because excessive bleeding may occur

  • Topical pain medicines (medicines applied to your skin) because some of these medicines may increase your risk of bleeding

  • Many prescription and nonprescription medicines (eg, used for allergic reactions, asthma, anxiety, gout, heartburn or reflux, HIV, infections, inflammation, aches and pains, heart problems, high blood pressure, high cholesterol, seizures, trouble sleeping, mental or mood problems, diabetes, stomach or bowel problems, irregular heartbeat, birth control, hormone replacement, cancer, immune system suppression, pulmonary arterial hypertension [PAH], and others), multivitamin products, and herbal or dietary supplements (eg, herbal teas, coenzyme Q10, garlic, ginseng, ginkgo, St. John's wort) may interact with Warfarin, increasing the risk of serious side effects such as bleeding or blood clots

This may not be a complete list of all interactions that may occur. Ask your health care provider if Warfarin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Warfarin:


Use Warfarin as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Warfarin comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Warfarin refilled.

  • Take Warfarin by mouth with or without food.

  • It is very important to take Warfarin on a regular schedule as prescribed by your doctor. Take Warfarin at the same time each day.

  • Continue to take Warfarin even if you feel well. Do not miss any doses, unless directed to do so by your doctor.

  • If you miss a dose of Warfarin, contact your doctor right away. Take the missed dose as soon as possible if you remember on the same day. If you do not remember until the next day, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Warfarin.



Important safety information:


  • Tell your doctor or dentist that you take Warfarin before you receive any medical or dental care, emergency care, or surgery.

  • Carry an ID card at all times that says you take Warfarin.

  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor. Contact your doctor right away if you may have taken too much of Warfarin.

  • Do not drink alcohol while you are taking Warfarin; it may increase the risk of Warfarin's side effects.

  • Do not change your activity level or weight without checking with your doctor; the risk of Warfarin's side effects may be increased. Do not participate in any sport or other activity that may cause a serious injury while taking Warfarin.

  • Do not change your eating habits without checking with your doctor. Eat a normal, balanced diet. Foods that have high levels of vitamin K in them (eg, green leafy vegetables, broccoli, liver, certain vegetable oils) may change the effect of Warfarin. Ask your doctor for a list of foods that may affect Warfarin. Tell your doctor if any foods on the list are a part of your diet.

  • Check with your doctor before you eat cranberries or grapefruit, or before you eat or drink products that contain cranberry or grapefruit while you are taking Warfarin. Tell your doctor if these products are already part of your diet.

  • Elevated body temperature may increase the effect of Warfarin. Be careful to avoid becoming overheated, especially during hot weather.

  • Warfarin decreases blood clotting. Use caution while doing activities such as brushing your teeth, flossing, or shaving. Avoid activities that may cause bruising or injury. Seek immediate medical attention if you fall or injure yourself. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Tell your doctor if you develop a fever, infection, or severe diarrhea

  • Do not take aspirin while you take Warfarin unless your doctor tells you to. If you already take aspirin for a heart or other condition, talk with your doctor about whether or not you should continue to take it with Warfarin.

  • Tell your doctor if you will be traveling or if you will be confined to a bed or chair for a long period of time (eg, car or airplane ride). This may increase your risk of developing a blood clot.

  • If therapy with Warfarin is stopped, the blood thinning effects may last for 2 to 5 days after you stop taking it. Discuss any questions or concerns with your doctor. Do not suddenly stop taking Warfarin without checking with your doctor.

  • Lab tests, including certain blood clotting tests (eg, PT, INR), may be performed while you use Warfarin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Warfarin with caution in Asian patients; they may be more sensitive to its effects, especially bleeding.

  • Use Warfarin with caution in the ELDERLY; they may be more sensitive to its effects, especially bleeding.

  • Warfarin should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed. Children may need more frequent lab tests if they use Warfarin.

  • If you may become pregnant, you must use an effective form of birth control while you take Warfarin. If you have questions about effective birth control, talk with your doctor.

  • PREGNANCY and BREAST-FEEDING: Do not use Warfarin if you are pregnant. It has been shown to cause harm to the fetus. Avoid becoming pregnant while you are taking it. If you think you may be pregnant, contact your doctor right away. It is not known if Warfarin is found in breast milk. If you are or will be breast-feeding while you use Warfarin, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Warfarin:


All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Warfarin. Seek medical attention right away if any of these SEVERE side effects occur:



Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); back, side, muscle, joint, or stomach pain; black, tarry, or bloody stools; blood in the urine (pink or brown urine); bloody or coffee ground-like vomit; chest pain; decreased urination; dizziness; fainting; fever; numbness or tingling; pain, unusual color, or temperature change in any area of the body; pale skin; purple, dark, or painful toes; shortness of breath; skin sores or ulcers; stroke symptoms (eg, confusion, slurred speech, vision problems, one-sided weakness); sudden, severe pain in your legs, feet, or toes; trouble swallowing; unexplained swelling; unusual bruising or bleeding (eg, nosebleed, unusual bleeding from gums, increased bleeding from cuts, increased menstrual or vaginal bleeding, coughing up blood); unusual headache or weakness; unusual pain, swelling, or discomfort; wounds or sores that do not heal properly; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Warfarin side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry stools; blood in stools or urine; increased menstrual bleeding; unusual bruising or bleeding.


Proper storage of Warfarin:

Store Warfarin at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Warfarin out of the reach of children and away from pets.


General information:


  • If you have any questions about Warfarin, please talk with your doctor, pharmacist, or other health care provider.

  • Warfarin is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Warfarin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Warfarin resources


  • Warfarin Side Effects (in more detail)
  • Warfarin Dosage
  • Warfarin Use in Pregnancy & Breastfeeding
  • Drug Images
  • Warfarin Drug Interactions
  • Warfarin Support Group
  • 22 Reviews for Warfarin - Add your own review/rating


Compare Warfarin with other medications


  • Antiphospholipid Syndrome
  • Chronic Central Venous Catheterization
  • Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
  • Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery
  • Deep Vein Thrombosis, First Event
  • Deep Vein Thrombosis, Recurrent Event
  • Heart Attack
  • Heart Failure
  • Prevention of Thromboembolism in Atrial Fibrillation
  • Prosthetic Heart Valves
  • Prosthetic Heart Valves, Mechanical Valves
  • Prosthetic Heart Valves, Tissue Valves
  • Protein S Deficiency
  • Pulmonary Embolism, First Event
  • Pulmonary Embolism, Recurrent Event
  • Thromboembolic Stroke Prophylaxis


Levothyroxine




Generic Name: Levothyroxine sodium

Dosage Form: tablet
Levothyroxine Sodium Tablets, USP

     


Levothyroxine Sodium Tablets, USP


Rx  only



DESCRIPTION


Levothyroxine sodium tablets, USP contains synthetic crystalline L-3,3’,5,5’-tetraiodothyronine sodium salt [Levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland.


Levothyroxine (T4) sodium has an empirical formula of C15H10I4N NaO4 x H2O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:




Inactive Ingredients


Magnesium Stearate, NF; Microcrystalline Cellulose, NF; Colloidal Silicone Dioxide, NF; Sodium Starch Glycolate, NF. The following are the color additives by tablet strength:




















































Strength (mcg)Color Additive(s)
25FD&C Yellow No. 6 Aluminum Lake
50None
75FD&C Blue No. 2 Aluminum Lake
D&C Red No. 27 Aluminum Lake
88FD&C Blue No. 1 Aluminum Lake
D&C Yellow No. 10 Aluminum Lake
D&C Red No. 30 Aluminum Lake
100D&C Yellow No. 10 Aluminum Lake
D&C Red Lake Blend (D&C Red No. 27 Lake and D&C Red No. 30 Lake)
112D&C Red No. 27 Aluminum Lake
D&C Red No. 30 Aluminum Lake
125FD&C Yellow No. 6 Aluminum Lake
FD&C Red No. 40 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake
137FD&C Blue No. 1 Aluminum Lake
150FD&C Blue No. 2 Aluminum Lake
175D&C Red No. 27 Aluminum Lake
D&C Red No. 30 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake
200D&C Yellow No. 10 Aluminum Lake
D&C Red No. 27 Aluminum Lake
300D&C Yellow No. 10 Aluminum Lake
FD&C Yellow No. 6 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake

CLINICAL PHARMACOLOGY


Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin-stimulating hormone, TSH, from the anterior pituitary. TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T4) and L-triiodothyronine (T3), by the thyroid gland. Circulating serum T3 and T4 levels exert a feedback effect on both TRH and TSH secretion. When serum T3 and T4 levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increase.


The mechanisms by which thyroid hormones exert their physiologic actions are not completely understood, but it is thought that their principal effects are exerted through control of DNA transcription and protein synthesis. T3 and T4 diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.


Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids. The protein anabolic effects of thyroid hormones are essential to normal growth and development.


The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.


Levothyroxine, at doses individualized according to patient response, is effective as replacement or supplemental therapy in hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.


Levothyroxine is also effective in the suppression of pituitary TSH secretion in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter and, as adjunctive therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (see INDICATIONS AND USAGE, PRECAUTIONS, DOSAGE AND ADMINISTRATION).



PHARMACOKINETICS


Absorption – Absorption of orally administered T4 from the gastrointestinal (GI) tract ranges from 40% to 80%. The majority of the Levothyroxine dose is absorbed from the jejunum and upper ileum. The relative bioavailability of this brand of Levothyroxine sodium tablets, USP product, compared to an equal nominal dose of oral Levothyroxine sodium solution, is approximately 99 %. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybean infant formula. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption (see PRECAUTIONS, Drug Interactions and Drug-Food Interactions).


Distribution – Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins (see PRECAUTIONS, Drug Interactions and Drug-Laboratory Test Interactions). Thyroid hormones do not readily cross the placental barrier (see PRECAUTIONS, Pregnancy).


Metabolism – T4 is slowly eliminated (see Table 1). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately eighty-percent of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.


Elimination – Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.



















Table 1: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
 Hormone Ratio in Thyroglobulin Biologic Potency t1/2 (days) Protein Binding (%)2
 Levothyroxine (T4) 10  -  20 1 6-71 99.96
 Liothyronine   (T3) 1 4 ≤ 2 99.5
 1  3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism; 2  Includes TBG, TBPA, and TBA

INDICATIONS AND USAGE


Levothyroxine sodium is used for the following indications:


Hypothyroidism – As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.  Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.


Pituitary TSH Suppression – In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS), including thyroid nodules (see WARNINGS and PRECAUTIONS), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.



CONTRAINDICATIONS


Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids (see PRECAUTIONS). Levothyroxine sodium tablets, USP is contraindicated in patients with hypersensitivity to any of the inactive ingredients in Levothyroxine sodium tablets, USP, (see DESCRIPTION, Inactive Ingredients.)



WARNINGS


WARNING:

Thyroid hormones, including Levothyroxine sodium tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.




Levothyroxine sodium should not be used in the treatment of male or female infertility unless this condition is associated with hypothyroidism.  In patients with nontoxic diffuse goiter or nodular thyroid disease, particularly the elderly or those with underlying cardiovascular disease, Levothyroxine sodium therapy is contraindicated if the serum TSH level is already suppressed due to the risk of precipitating overt thyrotoxicosis (see CONTRAINDICATIONS). If the serum TSH level is not suppressed, Levothyroxine sodium tablets, USP should be used with caution in conjunction with careful monitoring of thyroid function for evidence of hyperthyroidism and clinical monitoring for potential associated adverse cardiovascular signs and symptoms of hyperthyroidism.



PRECAUTIONS



General


Levothyroxine has a narrow therapeutic index. Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or under-treatment. These consequences include, among others, effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Many drugs interact with Levothyroxine sodium, necessitating adjustments in dosing to maintain therapeutic response (see Drug Interactions).


Effects on bone mineral density- In women, long-term Levothyroxine sodium therapy has been associated with increased bone resorption, thereby decreasing bone mineral density, especially in post-menopausal women on greater than replacement doses or in women who are receiving suppressive doses of Levothyroxine sodium. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase and suppressed serum parathyroid hormone levels. Therefore, it is recommended that patients receiving Levothyroxine sodium be given the minimum dose necessary to achieve the desired clinical and biochemical response.


Patients with underlying cardiovascular disease- Exercise caution when administering Levothyroxine to patients with cardiovascular disorders and to the elderly in whom there is an increased risk of occult cardiac disease. In these patients, Levothyroxine therapy should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease (see WARNINGS;PRECAUTIONS, Geriatric Use, and DOSAGE AND ADMINISTRATION). If cardiac symptoms develop or worsen, the Levothyroxine dose should be reduced or withheld for one week and then cautiously restarted at a lower dose. Overtreatment with Levothyroxine sodium may have adverse cardiovascular effects such as an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias. Patients with coronary artery disease who are receiving Levothyroxine therapy should be monitored closely during surgical procedures, since the possibility of precipitating cardiac arrhythmias may be greater in those treated with Levothyroxine. Concomitant administration of Levothyroxine and sympathomimetic agents to patients with coronary artery disease may precipitate coronary insufficiency.


Patients with nontoxic diffuse goiter or nodular thyroid disease- Exercise caution when administering Levothyroxine to patients with nontoxic diffuse goiter or nodular thyroid disease in order to prevent precipitation of thyrotoxicosis (see WARNINGS). If the serum TSH is already suppressed, Levothyroxine sodium should not be administered (see CONTRAINDICATIONS).



Associated endocrine disorders


Hypothalamic/pituitary hormone deficiencies- In patients with secondary or tertiary hypothyroidism, additional hypothalamic/pituitary hormone deficiencies should be considered, and, if diagnosed, treated (see PRECAUTIONS, Autoimmune polyglandular syndrome for adrenal insufficiency).



Autoimmune polyglandular syndrome


Occasionally, chronic autoimmune thyroiditis may occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious anemia, and insulin-dependent diabetes mellitus. Patients with concomitant adrenal insufficiency should be treated with replacement glucocorticoids prior to initiation of treatment with Levothyroxine sodium. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. Patients with diabetes mellitus may require upward adjustments of their antidiabetic therapeutic regimens when treated with Levothyroxine (see PRECAUTIONS, Drug Interactions).



Other associated medical conditions


Infants with congenital hypothyroidism appear to be at increased risk for other congenital anomalies, with cardiovascular anomalies (pulmonary stenosis, atrial septal defect, and ventricular septal defect) being the most common association.



Information for Patients


Patients should be informed of the following information to aid in the safe and effective use of Levothyroxine sodium tablets, USP:


  1. Notify your physician if you are allergic to any foods or medicines, are pregnant or intend to become pregnant, are breast-feeding or are taking any other medications, including prescription and over-the-counter preparations.

  2. Notify your physician of any other medical conditions you may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems. Your dose of medications used to control these other conditions may need to be adjusted while you are taking Levothyroxine sodium tablets, USP. If you have diabetes, monitor your blood and/or urinary glucose levels as directed by your physician and immediately report any changes to your physician. If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently.

  3. Use Levothyroxine sodium tablets, USP only as prescribed by your physician. Do not discontinue or change the amount you take or how often you take it, unless directed to do so by your physician.

  4. The Levothyroxine in Levothyroxine sodium tablets, USP is intended to replace a hormone that is normally produced by your thyroid gland. Generally, replacement therapy is to be taken for life, except in cases of transient hypothyroidism, which is usually associated with an inflammation of the thyroid gland (thyroiditis).

  5. Take Levothyroxine sodium tablets, USP as a single dose, preferably on an empty stomach, one-half to one hour before breakfast. Levothyroxine absorption is increased on an empty stomach.

  6. Levothyroxine sodium tablets, USP may rapidly disintegrate. It is very important that you take the tablet with a full glass of water.

  7. It may take several weeks before you notice an improvement in your symptoms.

  8. Notify your physician if you experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.

  9. Notify your physician if you become pregnant while taking Levothyroxine sodium tablets, USP. It is likely that your dose of Levothyroxine sodium tablets, USP will need to be increased while you are pregnant.

  10. Notify your physician or dentist that you are taking Levothyroxine sodium tablets, USP prior to any surgery.

  11. Partial hair loss may occur rarely during the first few months of Levothyroxine sodium tablets, USP therapy, but this is usually temporary.

  12. Levothyroxine sodium tablets, USP should not be used as a primary or adjunctive therapy in a weight control program.

  13. Keep Levothyroxine sodium tablets, USP out of the reach of children. Store Levothyroxine sodium tablets, USP away from heat, moisture, and light.

  14. Agents such as iron and calcium supplements and antacids can decrease the absorption of Levothyroxine sodium tablets. Therefore, Levothyroxine sodium tablets should not be administered within 4 hrs of these agents.


Laboratory Tests


General


The diagnosis of hypothyroidism is confirmed by measuring TSH levels using a sensitive assay (second generation assay sensitivity ≤ 0.1 mIU/L or third generation assay sensitivity ≤ 0.01 mIU/L) and measurement of free-T4.


The adequacy of therapy is determined by periodic assessment of appropriate laboratory tests and clinical evaluation. The choice of laboratory tests depends on various factors including the etiology of the underlying thyroid disease, the presence of concomitant medical conditions, including pregnancy, and the use of concomitant medications (see PRECAUTIONS, Drug Interactions and Drug-Laboratory Test Interactions). Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of Levothyroxine sodium tablets, USP may be evidence of inadequate absorption, poor compliance, drug interactions, or decreased T4 potency of the drug product.


Adults


In adult patients with primary (thyroidal) hypothyroidism, serum TSH levels (using a sensitive assay) alone may be used to monitor therapy. The frequency of TSH monitoring during Levothyroxine dose titration depends on the clinical situation but it is generally recommended at 6-8 week intervals until normalization. For patients who have recently initiated Levothyroxine therapy and whose serum TSH has normalized or in patients who have had their dosage of Levothyroxine changed, the serum TSH concentration should be measured after 8-12 weeks. When the optimum replacement dose has been attained, clinical (physical examination) and biochemical monitoring may be performed every 6-12 months, depending on the clinical situation, and whenever there is a change in the patient’s status. It is recommended that a physical examination and a serum TSH measurement be performed at least annually in patients receiving Levothyroxine sodium tablets, USP (see WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).


Pediatrics


In patients with congenital hypothyroidism, the adequacy of replacement therapy should be assessed by measuring both serum TSH (using a sensitive assay) and total- or free-T4. During the first three years of life, the serum total- or free-T4 should be maintained at all times in the upper half of the normal range. While the aim of therapy is to also normalize the serum TSH level, this is not always possible in a small percentage of patients, particularly in the first few months of therapy. TSH may not normalize due to a resetting of the pituitary-thyroid feedback threshold as a result of in utero hypothyroidism. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of Levothyroxine sodium tablets, USP therapy and/or of the serum TSH to decrease below 20 mU/L within 4 weeks should alert the physician to the possibility that the child is not receiving adequate therapy. Careful inquiry should then be made regarding compliance, dose of medication administered, and method of administration prior to raising the dose of Levothyroxine sodium tablets, USP.


The recommended frequency of monitoring of TSH and total- or free-T4 in children is as follows: at 2 and 4 weeks after the initiation of treatment; every 1-2 months during the first year of life; every 2-3 months between 1 and 3 years of age; and every 3 to 12 months thereafter until growth is completed. More frequent intervals of monitoring may be necessary if poor compliance is suspected or abnormal values are obtained. It is recommended that TSH and T4 levels, and a physical examination, if indicated, be performed 2 weeks after any change in Levothyroxine sodium tablets, USP dosage. Routine clinical examination, including assessment of mental and physical growth and development, and bone maturation, should be performed at regular intervals (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION).


Secondary (pituitary) and tertiary (hypothalamic) hypothyroidism


Adequacy of therapy should be assessed by measuring serum free-T4 levels, which should be maintained in the upper half of the normal range in these patients.



Drug Interactions


Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine sodium tablets, USP. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. A listing of drug-thyroidal axis interactions is contained in Table 2.


The list of drug-thyroidal axis interactions in Table 2 may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions. The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with Levothyroxine is suspected.
























































Table 2: Drug-Thyroidal Axis Interactions
 Drug or Drug Class Effect
 Drugs that may reduce TSH secretion–the reduction is not sustained; therefore, hypothyroidism does not occur
 Dopamine / Dopamine Agonists

Glucocorticoids

Octreotide
 Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: Dopamine ( ≥ 1 µg/kg/min); Glucocorticoids (hydrocortisone ≥ 100 mg/day or equivalent); Octreotide ( > 100 µg/day).
 Drugs that alter thyroid hormone secretion
 Drugs that may decrease thyroid hormone secretion, which may result in hypothyroidism
 Aminoglutethimide

Amiodarone

Iodide(including iodine-containing

  Radiographic contrast agents)

Lithium

Methimazole

Propylthiouracil (PTU)

Sulfonamides

Tolbutamide
 Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients.  The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto’s thyroiditis or with Grave’s disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. Long-term aminoglutethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.
 Drugs that may increase thyroid hormone secretion, which may result in hyperthyroidism
 Amiodarone

Iodide(including iodine-containing   

  Radiographic contrast agents)
 Iodide and drugs that contain pharmacological amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave’s disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyperfunctioning thyroid adenoma).  Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. Amiodarone may induce hyperthyroidism by causing thyroiditis.
 Drugs that may decrease T4 absorption, which may result in hypothyroidism
 Antacids

- Aluminum & Magnesium Hydroxides

- Simethicone

Bile Acid Sequestrants

- Cholestyramine

- Colestipol

Calcium Carbonate

Cation Exchange Resins

- Kayexalate

Ferrous Sulfate

Orlistat

Sucralfate
 Concurrent use may reduce the efficacy of Levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.  Calcium carbonate may form an insoluble chelate with Levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer Levothyroxine at least 4 hours apart from these agents.  Patients treated concomitantly with orlistat and Levothyroxine should be monitored for changes in thyroid function.
 Drugs that may alter T4 and T3 serum transport  - but FT4 concentration remains normal; and, therefore, the patient remains euthyroid
 Drugs that may increase serum TBG concentration Drugs that may decrease serum TBG concentration
 Clofibrate

Estrogen-containing oral contraceptives

Estrogens (oral)

Heroin / Methadone

5-Fluorouracil

Mitotane

Tamoxifen
 Androgens / Anabolic Steroids

Asparaginase

Glucocorticoids

Slow-Release Nicotinic Acid
 Drugs that may cause protein-binding site displacement
 Furosemide (> 80 mg IV)

Heparin

Hydantoins

Non Steroidal Anti-Inflammatory Drugs

- Fenamates

- Phenylbutazone

Salicylates (> 2 g/day)
 Administration of these agents with Levothyroxine results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4, and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%.
 Drugs that may alter T4 and T3 metabolism
 Drugs that may increase hepatic metabolism, which may result  in hypothyroidism
 Carbamazepine

Hydantoins

Phenobarbital

Rifampin
 Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of Levothyroxine, resulting in increased Levothyroxine requirements. Phenytoin and carbamazepine reduce serum protein binding of Levothyroxine, and total- and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.
 Drugs that may decrease T4 5’-deiodinase activity
 Amiodarone

Beta-adrenergic antagonists

- (e.g., Propranolol > 160 mg/day)

Glucocorticoids

- (e.g., Dexamethasone ≥ 4 mg/day)

Propylthiouracil (PTU)
 Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased. In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4  levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).
 Miscellaneous
 Anticoagulants (oral)

- Coumarin Derivatives

- Indandione Derivatives
 Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants. Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis. Prothrombin time should be carefully monitored in patients taking Levothyroxine and oral anticoagulants and the dose of anticoagulant therapy adjusted accordingly.
 Antidepressants

- Tricyclics (e.g., Amitriptyline)

- Tetracyclics (e.g., Maprotiline)

- Selective Serotonin Reuptake Inhibitors

  (SSRIs; e.g., Sertraline)
 Concurrent use of tri/tetracyclic antidepressants and Levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; onset of action of  tricyclics may be accelerated. Administration of sertraline in patients stabilized on Levothyroxine may result in increased Levothyroxine requirements.
 Antidiabetic Agents

- Biguanides

- Meglitinides

- Sulfonylureas

- Thiazolidinediones

- Insulin
 Addition of Levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.
 Cardiac Glycosides Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state. Therapeutic effect of digitalis glycosides may be reduced.
 Cytokines

- Interferon-α

- Interleukin-2
 Therapy with interferon-α has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. Interferon-β and -γ have not been reported to cause thyroid dysfunction.
 Growth Hormones

- Somatrem

- Somatropin
 Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure. However, untreated hypothyroidism may interfere with growth response to growth hormone.
 Ketamine Concurrent use may produce marked hypertension and tachycardia; cautious administration to patients receiving thyroid hormone therapy is recommended.
 Methylxanthine Bronchodilators

- (e.g., Theophylline)
 Decreased theophylline clearance may occur in hypothyroid patients; clearance returns to normal when the euthyroid state is achieved.
 Radiographic Agents Thyroid hormones may reduce the uptake of 123I, 131I, and 99mTc.
 Sympathomimetics Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
 Chloral Hydrate

Diazepam

Ethionamide

Lovastatin

Metoclopramide

6-Mercaptopurine

Nitroprusside

Para-aminosalicylate sodium

Perphenazine

Resorcinol (excessive topical use)

Thiazide Diuretics
 These agents have been associated with thyroid hormone and / or TSH level alterations by various mechanisms.

Oral anticoagulants- Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine sodium tablets, USP dose is increased. Prothrombin time should be closely monitored to permit appropriate and timely dosage adjustments (see Table 2).


Digitalis glycosides- The therapeutic effects of digitalis glycosides may be reduced by Levothyroxine. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides (see Table 2).


Drug-Food Interactions - Consumption of certain foods may affect Levothyroxine absorption thereby necessitating adjustments in dosing. Soybean flour (infant formula), cotton seed meal, walnuts, and dietary fiber may bind and decrease the absorption of Levothyroxine sodium from the GI tract.


Drug-Laboratory Test Interactions - Changes in TBG concentration must be considered when interpreting T4 and T3 values, which necessitates measurement and evaluation of unbound (free) hormone and/or determination of the free-T4 index (FT4I). Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Decreases in TBG concentrations are observed in nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and after androgen or corticosteroid therapy (see also Table 2). Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.


Carcinogenesis, Mutagenesis, and Impairment of Fertility - Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of Levothyroxine. The synthetic T4 in Levothyroxine sodium tablets, USP is identical to that produced naturally by the human thyroid gland. Although there has been a reported association between prolonged thyroid hormone therapy and breast cancer, this has not been confirmed. Patients receiving Levothyroxine sodium tablets, USP for appropriate clinical indications should be titrated to the lowest effective replacement dose.


Pregnancy - Category A – Studies in women taking Levothyroxine sodium during pregnancy have not shown an increased risk of congenital abnormalities. Therefore, the possibility of fetal harm appears remote. Levothyroxine sodium tablets, USP should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.


Hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, pre-eclampsia, stillbirth and premature delivery. Maternal hypothyroidism may have an adverse effect on fetal and childhood growth and development. During pregnancy, serum T4 levels may decrease and serum TSH levels increase to values outside the normal range. Since elevations in serum TSH may occur as early as 4 weeks gestation, pregnant women taking Levothyroxine sodium tablets, USP should have their TSH measured during each trimester. An elevated serum TSH level should be corrected by an increase in the dose of Levothyroxine sodium tablets, USP. Since postpartum TSH levels are similar to preconception values, the Levothyroxine sodium tablets, USP dosage should return to the pre-pregnancy dose immediately after delivery.  A serum TSH level should be obtained 6-8 weeks postpartum.


Thyroid hormones cross the placental barrier to some extent as evidenced by levels in cord blood of athyreotic fetuses being approximately one-third maternal levels. Transfer of thyroid hormone from the mother to the fetus, however, may not be adequate to prevent in utero hypothyroidism.


Nursing Mothers - Although thyroid hormones are excreted only minimally in human milk, caution should be exercised when Levothyroxine sodium tablets, USP are administered to a nursing woman. However, adequate replacement doses of Levothyroxine are generally needed to maintain normal lactation.



Pediatric Use


General


The goal of treatment in pediatric patients with hypothyroidism is to achieve and maintain normal intellectual and physical growth and development.


The initial dose of Levothyroxine varies with age and body weight (see DOSAGE AND ADMINISTRATION, Table 3). Dosing adjustments are based on an assessment of the individual patient’s clinical and laboratory parameters (see PRECAUTIONS, Laboratory Tests).


In children in whom a diagnosis of permanent hypothyroidism has not been established, it is recommended that Levothyroxine administration be discontinued for a 30-day trial period, but only after the child is at least 3 years of age. Serum T4 and TSH levels should then be obtained. If the T4 is low and the TSH high, the diagnosis of permanent hypothyroidism is established, and Levothyroxine therapy should be reinstituted. If the T4 and TSH levels are normal, euthyroidism may be assumed and, therefore, the hypothyroidism can be considered to have been transient. In this instance, however, the physician should carefully monitor the child and repeat the thyroid function tests if any signs or symptoms of hypothyroidism develop. In this setting, the clinician should have a high index of suspicion of relapse. If the results of the Levothyroxine withdrawal test are inconclusive, careful follow-up and subsequent testing will be necessary.


Since some more severely affected children may become clinically hypothyroid when treatment is discontinued for 30 days, an alternate approach is to reduce the replacement dose of Levothyroxine by half during the 30-day trial period. If, after 30 days, the serum TSH is elevated above 20 mU/L, the diagnosis of permanent hypothyroidism is confirmed, and full replacement therapy should be resumed. However, if the serum TSH has not risen to greater than 20 mU/L, Levothyroxine treatment should be discontinued for another 30-day trial period followed by repeat serum T4 and TSH testing.


The presence of concomitant medical conditions should be considered in certain clinical circumstances and, if present, appropriately treated (see PRECAUTIONS).


Congenital Hypothyroidism (see PRECAUTIONS, Laboratory Tests and DOSAGE and ADMINISTRATION)


Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, Levothyroxine sodium tablets, USP therapy should be initiated immediately upon diagnosis and is generally continued for life.


During the first 2 weeks of Levothyroxine sodium tablets, USP therapy, infants should be closely monitored for cardiac overload, arrhythmias, and aspiration from avid suckling.


The patient should be monitored closely to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment has been associated with craniosynostosis in infants, and may adversely affect the tempo of brain maturation and accelerate the bone age with resultant premature closure of the epiphyses and compromised adult stature.


Acquired Hypothyroidism in Pediatric Patients


The patient should be monitored closely to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.


Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.



Geriatric Use


Because of the increased prevalence of cardiovascular disease among the elderly, Levothyroxine therapy should not be initiated at the full replacement dose (see WARNINGS,PRECAUTIONS, and DOSAGE AND ADMINISTRATION).



ADVERSE REACTIONS


Adverse reactions associated with Levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage (see PRECAUTIONS and OVERDOSAGE). They include the following:

General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating;

Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia;

Musculoskeletal: tremors, muscle weakness;

Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest;

Respiratory: dyspnea;

Gastrointestinal: diarrhea, vomiting, abdominal cramps and elevations in liver function tests;

Dermatologic: hair loss, flushing;

Endocrine: decreased bone mineral density;

Reproductive: menstrual irregularities, impaired fertility.


Pseudotumor cerebri and slipped capital femoral epiphyses have been reported in children receiving Levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.


Seizures have been reported rarely with the institution of Levothyroxine therapy.


Inadequate Levothyroxine dosage will produce or fail to ameliorate the signs and symptoms of hypothyroidism.


Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to Levothyroxine itself is not known to occur.



OVERDOSAGE


The signs and symptoms of overdosage are those of hyperthyroidism (see PRECAUTIONS and ADVERSE REACTIONS). In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures have occurred in a child ingesting 18 mg of Levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of Levothyroxine sodium.



Treatment of Overdosage


Levothyroxine sodium should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur.


      Acute Massive Overdosage – This may be a life-threatening emergency, therefore, symptomatic and supportive therapy should be instituted immediately. If not contraindicated (e.g., by seizures, coma, or loss of the gag reflex), the stomach should be emptied by emesis or gastric lavage to decrease gastrointestinal absorption. Activated charcoal or cholestyramine may also be used to decrease absorption. Central and peripheral increased sympathetic activity may be treated by administering β-receptor antagonists, e.g., propranolol, provided there are no medical contraindications to their use. Provide respiratory support as needed; control congestive heart failure and arrhythmia; control fever, hypoglycemia, and fluid loss as necessary. Large doses of antithyroid drugs (e.g., methimazole or propylthiouracil) followed in one to two hours by large doses of iodine may be given to inhibit synthesis and release of thyroid hormones. Glucocorticoids may be given to inhibit the conversion of T4 to T3. Plasmapheresis, charcoal hemoperfusion, and exchange transfusion have been reserved for cases in which continued clinical deterioration occurs despite conventional therapy. Because T4 is highly protein bound, very little drug will be removed by dialysis.



DOSAGE AND ADMIN


Multivitamins with Folic Acid/Iron


Pronunciation: muhl-tee-VYE-ta-mins/FOE-lik AS-id/EYE-urn
Generic Name: Multivitamins with Folic Acid/Iron
Brand Name: Examples include Ferocon and TL Icon

Accidental overdose of products that contain iron is a leading cause of fatal poisoning in children younger than 6 years old. Keep this and all medicines out of the reach of children. In case of accidental ingestion, call a doctor or poison control center right away.





Multivitamins with Folic Acid/Iron is used for:

Treating or preventing low levels of vitamins, folic acid, and iron in the body. It may also be used for other conditions as determined by your doctor.


Multivitamins with Folic Acid/Iron is a vitamin, folic acid, and iron supplement. It works by providing extra vitamins, folic acid, and iron to the body when you need more than what you get in your diet.


Do NOT use Multivitamins with Folic Acid/Iron if:


  • you are allergic to any ingredient in Multivitamins with Folic Acid/Iron

  • you have certain iron metabolism problems (eg, hemosiderosis, hemochromatosis) or high levels of iron in your blood

Contact your doctor or health care provider right away if any of these apply to you.



Before using Multivitamins with Folic Acid/Iron:


Some medical conditions may interact with Multivitamins with Folic Acid/Iron. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have bowel problems (eg, colitis, Crohn disease, diverticulitis), certain blood disorders (eg, hemolytic or pernicious anemia, porphyria cutanea tarda, thalassemia), glucose-6-phosphate-dehydrogenase (G6PD) deficiency, or a peptic ulcer

  • if you have had multiple blood transfusions

Some MEDICINES MAY INTERACT with Multivitamins with Folic Acid/Iron. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Fluorouracil because the risk of its side effects may be increased by Multivitamins with Folic Acid/Iron

  • Cephalosporin antibiotics (eg, cephalexin), eltrombopag, hydantoins (eg, phenytoin), methyldopa, mycophenolate, penicillamine, quinolone antibiotics (eg, ciprofloxacin), tetracycline antibiotics (eg, doxycycline), or thyroid hormones (eg, levothyroxine) because their effectiveness may be decreased by Multivitamins with Folic Acid/Iron

This may not be a complete list of all interactions that may occur. Ask your health care provider if Multivitamins with Folic Acid/Iron may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Multivitamins with Folic Acid/Iron:


Use Multivitamins with Folic Acid/Iron as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Multivitamins with Folic Acid/Iron by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • Take Multivitamins with Folic Acid/Iron with a full glass of water (8 oz/240 mL).

  • Do not take an antacid within 1 hour before or 2 hours after you take Multivitamins with Folic Acid/Iron.

  • Avoid taking Multivitamins with Folic Acid/Iron with dairy products; they may interfere with the absorption of the iron in Multivitamins with Folic Acid/Iron.

  • If you miss a dose of Multivitamins with Folic Acid/Iron, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Multivitamins with Folic Acid/Iron.



Important safety information:


  • Do not take large doses of vitamins while you use Multivitamins with Folic Acid/Iron unless your doctor tells you to.

  • Multivitamins with Folic Acid/Iron may discolor the stools. This is normal and not a cause for concern.

  • Multivitamins with Folic Acid/Iron has iron in it. Iron overdose is a leading cause of fatal poisoning in children younger than 6 years old. In case of an overdose, call a doctor or poison control center right away.

  • Multivitamins with Folic Acid/Iron has folic acid and iron in it. Before you start any new medicine, check the label to see if it has folic acid or iron in it too. If it does not or if you are not sure, check with your doctor or pharmacist.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Multivitamins with Folic Acid/Iron while you are pregnant. It is not known if Multivitamins with Folic Acid/Iron is found in breast milk. If you are or will be breast-feeding while you use Multivitamins with Folic Acid/Iron, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Multivitamins with Folic Acid/Iron:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; dark or discolored stools; diarrhea; nausea; stomach upset; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; blood in the vomit; persistent nausea, vomiting, or diarrhea; stomach pain or cramping.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry stools; blood in the vomit; diarrhea; headache; nausea; vomiting.


Proper storage of Multivitamins with Folic Acid/Iron:

Store Multivitamins with Folic Acid/Iron at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Multivitamins with Folic Acid/Iron out of the reach of children and away from pets.


General information:


  • If you have any questions about Multivitamins with Folic Acid/Iron, please talk with your doctor, pharmacist, or other health care provider.

  • Multivitamins with Folic Acid/Iron is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Multivitamins with Folic Acid/Iron. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Multivitamins with Folic Acid/Iron resources


  • Multivitamins with Folic Acid/Iron Use in Pregnancy & Breastfeeding
  • Drug Images
  • Multivitamins with Folic Acid/Iron Drug Interactions
  • Multivitamins with Folic Acid/Iron Support Group
  • 11 Reviews for Multivitamins with Folic Acid/Iron - Add your own review/rating


Compare Multivitamins with Folic Acid/Iron with other medications


  • Anemia
  • Vitamin/Mineral Supplementation and Deficiency